Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

Po-Hsien Li*, Cheng-Hsien Lin*, Yu-Hui Lin, Tsung-Chih Chen, Chiann-Yi Hsu and Chieh-Lin Jerry Teng

Abstract

Background: Letermovir prophylaxis is currently the standard of care for the prevention of cytomegalovirus (CMV) infections in allogeneic hematopoietic stem-cell transplantation (allo-HSCT). However, drug–drug interactions between letermovir and azoles or calcineurin inhibitors and the high financial burden of letermovir remain problematic, especially in resource-limited countries. It has not been clarified whether a lower dose of valganciclovir would constitute an effective strategy for CMV prevention in patients with acute leukemia undergoing allo-HSCT.

Methods: We retrospectively assessed 84 consecutive adult patients with acute leukemia who underwent allo-HSCT. These 84 patients were stratified into a valganciclovir prophylaxis group (n = 20) and a non-valganciclovir prophylaxis group (n = 64).

Results: Patients in the valganciclovir prophylaxis group had a lower possibility of CMV DNAemia at week 14 after allo-HSCT than those in the non-valganciclovir prophylaxis group (15.0% versus 50.0%; p = 0.012). The cumulative incidence of CMV DNAemia at week 14 was also lower in patients with valganciclovir CMV prophylaxis than in those without (15.0% versus 50.4%; p = 0.006). Multivariate analysis validated these data, showing that a low dose of valganciclovir significantly reduced the risk of CMV DNAemia at week 14 by 88% (hazard ratio: 0.12; 95% confidence interval: 0.04–0.42; p = 0.001). However, these two groups had similar overall survival rates at week 48 (75.0% versus 76.6%; p = 0.805). Four of 20 (20%) patients discontinued valganciclovir prophylaxis because of adverse events.

Conclusion: Low-dose valganciclovir prophylaxis could be an alternative to letermovir to prevent CMV infection in allo-HSCT, especially in resource-limited countries.

Keywords: allo-HSCT, CMV, leukemia, prophylaxis, valganciclovir

Introduction

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a necessary treatment for various hematological diseases. For patients with acute myeloid leukemia with intermediate- and poor-risk cytogenetic and molecular features, allo-HSCT is considered the preferred post-remission therapy. In terms of acute lymphoblastic leukemia, complex, Philadelphia, or other high-risk chromosome abnormalities at diagnosis, and persistent minimal residual disease detected with multicolor flow cytometry, polymerase chain reaction assay for B cell immunoglobulin and T cell receptor gene rearrangements, or next-generation sequencing after remission induction chemotherapy are indications for allo-HSCT. Although allo-HSCT provides a survival benefit, it can also lead to serious complications, including CMV infection. CMV DNAemia is an indicator of CMV infection and is associated with poorer survival outcomes. To prevent CMV infection, many clinicians have used antiviral prophylaxis agents such as valganciclovir. However, the high cost of letermovir and the potential drug–drug interactions with letermovir remain problematic, especially in resource-limited countries. It has not been clarified whether a lower dose of valganciclovir could be an alternative for CMV prevention in patients with acute leukemia undergoing allo-HSCT.
benefit to patients with acute leukemia, infection remains a profound complication and may result in transplant-related mortality. After allo-HSCT, cytomegalovirus (CMV) is notorious among the numerous types of infectious agents because CMV infection may cause multiorgan diseases in allo-HSCT recipients.³

Currently, preemptive therapies and prophylaxis are the two primary strategies to prevent CMV diseases in allo-HSCT. A European conference on infections in leukemia has proposed preemptive intravenous ganciclovir or oral valganciclovir as the drug of choice for asymptomatic allo-HSCT recipients with detected CMV DNAemia greater than 1000 copies/mL.⁴ Regarding preventive strategies, CMV prophylaxis in allo-HSCT started with acyclovir in 1981. With delayed CMV reactivation, acyclovir prophylaxis did not effectively prevent CMV diseases in allo-HSCT.⁵ The second CMV preventive agent studied was ganciclovir. Unlike acyclovir, intravenous ganciclovir prophylaxis significantly reduced the risk of CMV infection in allo-HSCT. However, ganciclovir prophylaxis was not associated with reduction in all-cause mortality in allo-HSCT.⁶ Additionally, ganciclovir-induced myelosuppression remains an unresolved issue. Long-term intravenous ganciclovir administration is also impractical. In the past decade, maribavir and brincidofovir have emerged as potential candidates for CMV prophylaxis in allo-HSCT. However, a phase III trial by Marty et al.⁷ failed to show that preventive maribavir could effectively reduce the incidence of CMV disease, reactivation, or probability of CMV preemptive therapy during allo-HSCT. In addition, intolerable adverse events negatively impact the clinical application of brincidofovir in the allo-HSCT setting.⁸

Letermovir is currently the standard of care for CMV prophylaxis in allo-HSCT because a 14-week prophylactic course of letermovir has been shown to significantly decrease CMV infection by 23.5% at week 24.⁹ However, drug–drug interactions between letermovir and azoles or calcineurin inhibitors require more attention. Moreover, the associated high financial burden remains a concern, especially in resource-limited countries. To avoid the inconvenience of intravenous ganciclovir administration and the drug–drug interactions between letermovir and azoles or calcineurin inhibitors, oral valganciclovir could be an alternative to prevent CMV infection in allo-HSCT. A randomized controlled study showed that compared with preemptive CMV treatment, late prevention with daily 900 mg valganciclovir did not improve CMV disease-free survival. In addition, a greater degree of treatment-related neutropenia was observed in patients undergoing late valganciclovir prophylaxis.¹⁰

Whether early intervention with a lower dose of valganciclovir would be an effective and safe strategy for CMV prophylaxis in patients with acute leukemia undergoing allo-HSCT remains unclear. Accordingly, we conducted this retrospective study to compare the incidence of CMV DNAemia at week 14 after allo-HSCT among patients with acute leukemia with and without low-dose valganciclovir prophylaxis to address the possible application of low-dose valganciclovir in this setting. We also analyzed the overall survival (OS) difference at week 48 between these two groups of patients.

**Methods**

**Patients**

We retrospectively reviewed the medical records of 84 consecutive adult patients with acute leukemia in complete remission undergoing allo-HSCT at our hospital between February 2010 and December 2019. To investigate the impact of CMV prophylaxis with a low dose of valganciclovir in patients with acute leukemia receiving allo-HSCT, these 84 patients were further stratified into the valganciclovir prophylaxis group (*n* = 20) and the non-valganciclovir prophylaxis group (*n* = 64). There were no significant differences in age (*p* = 0.629), sex (*p* = 0.442), donor type (*p* = 0.139), and CMV serostatus for both donors and recipients (*p* = 0.534), and types of conditioning regimens (*p* = 0.121) between the groups. The median day of absolute neutrophil engraftment for the valganciclovir prophylaxis and non-valganciclovir prophylaxis groups was 13.0 and 11.5 days, respectively (*p* = 0.069). However, patients in the valganciclovir prophylaxis group had a higher proportion of anti-thymocyte globulin (ATG) use for graft-versus-host disease (GVHD) prophylaxis than patients in the non-valganciclovir prophylaxis group (100% versus 67.2%; *p* = 0.008). Because we started to use
low-dose valganciclovir prophylaxis in January 2018, the patients without valganciclovir prophylaxis were followed up for a longer period than the patients with valganciclovir prophylaxis (37.2 months versus 15.7 months; \( p = 0.001 \)) (Table 1). The Institutional Review Board of the Taichung Veterans General Hospital approved the study in accordance with the current version of the Declaration of Helsinki (CE20309B). The Institutional Review Board agreed to waive the requirement for informed consent for the patients enrolled in this retrospective study.

**Immunosuppressants for GVHD prophylaxis**

We used cyclosporine as the primary immunosuppressant for GVHD prophylaxis since day \( -2 \) for patients allografted from both matched sibling donors and matched unrelated donors. A trough level between 150 and 250 ng/mL was the target concentration of cyclosporine. We gradually reduced the cyclosporine dose after day 90. Rabbit ATG (2 mg·kg\(^{-1}\)·day\(^{-1}\), from day \(-3\) to day \(-2\)) was routinely administered to patients allografted from matched unrelated donors, but it was not mandatory for patients allografted from matched sibling donors. For haploidentical allo-HSCT, we implemented a GVHD prophylaxis strategy modified from the Johns Hopkins protocol.\(^{11}\) Briefly, in addition to post-transplantation cyclophosphamide, patients undergoing haploidentical allo-HSCT also received both cyclosporine (since day \( 5 \)) and rabbit ATG (2 mg·kg\(^{-1}\)·day\(^{-1}\), from day \(-3\) to day \(-2\)) as part of their immunosuppressants’ regimen. To further prevent GVHD, we used myfortic acid at a dose of 720 mg twice daily starting on day \(-2\) for patients allografted from matched sibling donors and matched unrelated donors and on day \( 5 \) for patients undergoing haploidentical allo-HSCT. Myfortic acid was discontinued on day 60.

**CMV monitoring, prophylaxis, and preemptive treatment**

We used the quantitative polymerase chain reaction assay of the COBAS® AmpliPrep/COBAS TaqMan CMV system (Roche Molecular Systems, Inc., Branchburg, NJ, USA) to monitor serum CMV DNAemia. This monitoring was conducted before allo-HSCT and once a week in the first 14 weeks after allo-HSCT. After week 14, we generally monitored for CMV DNAemia every 2 weeks until week 48. Notably, none of the allo-HSCT recipients in the current study were detected to have CMV DNAemia before allo-HSCT.

Regarding CMV prophylaxis, patients in the valganciclovir prophylaxis group received valganciclovir 450 mg per day, from the day of absolute neutrophil engraftment to approximately 100 days after allo-HSCT. The median duration of valganciclovir prophylaxis was 98.5 (range: 21–107) days. In contrast, patients in the non-valganciclovir prophylaxis group did not receive any prophylaxis for CMV. Preemptive antiviral therapy with ganciclovir and CMV-specific intravenous immunoglobulin started when the CMV viral load exceeded 1000 copies/mL in both groups of patients. The preemptive treatment continued until CMV DNAemia was no longer detected.

**Outcome measurements and definitions**

Comparison of the incidence of CMV DNAemia at week 14 between the valganciclovir prophylaxis group and non-valganciclovir prophylaxis group to identify whether a low dose of valganciclovir prophylaxis could decrease CMV DNAemia in allo-HSCT was the primary outcome measurement in the current study. This study also compared the difference in the OS rate at week 48 between the groups. The incidence of GVHD and relapse rate and causes of death were further analyzed (Figure 1).

Regarding causes of death, death before week 14 after allo-HSCT was considered to constitute transplant-related mortality. Furthermore, we defined acute leukemia as the cause of death if leukemia cells were still identified from either peripheral blood or bone marrow at the time of death. GVHD was considered the cause of death if GVHD and CMV DNAemia or CMV diseases were simultaneously active at the time of death.

**Statistical analysis**

Continuous variables were compared between the valganciclovir and non-valganciclovir prophylaxis groups using the Mann–Whitney \( U \) test. Categorical variables were analyzed using the chi-square test or Fisher’s exact test, as indicated. We used Cox proportional regression to identify risk factors of CMV DNAemia at week 14, quantified...
|                                | All patients | Non-valganciclovir prophylaxis | Valganciclovir prophylaxis | p-value |
|--------------------------------|--------------|--------------------------------|----------------------------|---------|
| **Age, median (range), years** | 43 (18–74)  | 42.5 (19–74)                   | 44.0 (18–70)               | 0.629§  |
| **Sex, n [%]**                  |              |                                |                            | 0.442¶  |
| Male                           | 42 (50.0%)   | 30 (46.9%)                     | 12 (60.0%)                 |         |
| Female                         | 42 (50.0%)   | 34 (53.1%)                     | 8 (40.0%)                  |         |
| **Diagnosis, n [%]**           |              |                                |                            | 0.468¶  |
| Acute myeloid leukemia         | 58 (69.1%)   | 46 (71.9%)                     | 12 (60.0%)                 |         |
| Acute lymphoblastic leukemia   | 26 (31.0%)   | 18 (28.1%)                     | 8 (40.0%)                  |         |
| **Donor types, n [%]**         |              |                                |                            | 0.139¶  |
| MSD                            | 37 (44.1%)   | 31 (48.4%)                     | 6 (30.0%)                  |         |
| MUD                            | 20 (23.8%)   | 16 (25.0%)                     | 4 (20.0%)                  |         |
| Haploidentical donor           | 27 (32.1%)   | 17 (26.6%)                     | 10 (50.0%)                 |         |
| **CMV serology, n [%]**        |              |                                |                            | 0.534¶  |
| D+/R+                          | 53 (63.1%)   | 42 (65.6%)                     | 11 (55.0%)                 |         |
| D+/R−                          | 11 (13.1%)   | 8 (12.5%)                      | 3 (15.0%)                  |         |
| D−/R+                          | 13 (15.5%)   | 9 (14.1%)                      | 4 (20.0%)                  |         |
| D−/R−                          | 3 (3.6%)     | 3 (4.7%)                       | 0 (0.0%)                   |         |
| **Conditioning regimen, n [%]**|              |                                |                            | 0.121¶  |
| Myeloablative                  | 47 (56.0%)   | 38 (59.4%)                     | 9 (45.0%)                  |         |
| Reduced intensity              | 10 (11.9%)   | 9 (14.1%)                      | 1 (5.0%)                   |         |
| Haploidentical                 | 27 (32.1%)   | 17 (26.6%)                     | 10 (50.0%)                 |         |
| **ATG, n [%]**                 |              |                                |                            | 0.008¶  |
| No                             | 21 (25.0%)   | 21 (32.8%)                     | 0 (0.0%)                   |         |
| Yes                            | 63 (75.0%)   | 43 (67.2%)                     | 20 (100%)                  |         |
| **ANC engraftment time, median (range), days** | 12.0 (8–21) | 11.5 (8–21) | 13.0 (10–20) | 0.069§ |
| **Platelet engraftment time, median (range), days** | 11.0 (7–26) | 11.0 (7–25) | 13.0 (9–26) | 0.119§ |
| **Follow-up time, median (range), months** | 26.2 (1.4–126.5) | 37.2 (1.4–126.5) | 15.7 (3.0–30.8) | 0.001§ |

§Chi-square test.
ANC, absolute neutrophil count; ATG, anti-thymocyte globulin; CMV, cytomegalovirus; D, donor; MSD, matched sibling donor; MUD, matched unrelated donor; R, recipient.
as hazard ratios (HRs) and their accompanying 95% confidence intervals (CIs). Age, sex, donor types, ATG administration, conditioning intensity, CMV serostatus, and valganciclovir prophylaxis were the risk factors included as potential factors in the univariate analysis. Only factors found to be statistically significant in the univariate analysis were included in the multivariate analysis. The Fine–Gray test was used to investigate the difference in the cumulative incidence of CMV DNAemia at week 14 between the valganciclovir and non-valganciclovir prophylaxis groups was 15.0% and 50.4%, respectively, with the difference between the groups being significant ($p=0.006$).

Figure 1. Comparison of the cumulative incidence of cytomegalovirus (CMV) DNAemia between the study groups. The cumulative incidence of CMV DNAemia at week 14 after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in the valganciclovir and non-valganciclovir prophylaxis groups was 15.0% and 50.4%, respectively, with the difference between the groups being significant ($p=0.006$).

Results

The patients in the valganciclovir prophylaxis group had a lower incidence of CMV DNAemia at week 14 than the patients in the non-valganciclovir prophylaxis group.

The incidence of CMV DNAemia at week 14 after allo-HSCT was 15.0% and 50.0% in the valganciclovir and non-valganciclovir prophylaxis groups, respectively ($p=0.012$) (Table 2). To consider the impacts of competing risks, we compared the cumulative incidence of CMV DNAemia at week 14 between the groups using the Fine–Gray test. The results showed that the cumulative incidence of CMV DNAemia at week 14 in the valganciclovir and non-valganciclovir prophylaxis groups was 15.0% and 50.4%, respectively ($p=0.006$).

Low-dose valganciclovir prophylaxis significantly reduced the risk of CMV DNAemia at week 14.

Next, we investigated the risk factors for CMV DNAemia at week 14 in patients with acute leukemia undergoing allo-HSCT. Univariate analysis revealed that older age (HR, 1.02; 95% CI, 1.00–1.05; $p=0.044$) and allografting from matched unrelated donors (HR, 2.61; 95% CI, 1.06–6.43; $p=0.037$) or haploidentical donors (HR, 3.70; 95% CI, 1.63–8.40; $p=0.002$) were associated with a higher incidence of CMV DNAemia at week 14 after allo-HSCT. In contrast, conditioning with myeloablative regimens (HR, 0.30; 95% CI, 0.15–0.60; $p=0.001$) and low-dose valganciclovir prophylaxis (HR, 0.23; 95% CI, 0.07–0.75; $p=0.015$) significantly decreased the risks of CMV DNAemia.

The multivariate analysis further validated this result, showing that allografting from matched unrelated donors (HR, 2.90; 95% CI, 1.16–7.29; $p=0.023$) and haploidentical donors (HR, 5.34; 95% CI, 1.70–16.83; $p=0.004$) increased the risk of CMV DNAemia. More importantly, a low dose of valganciclovir prophylaxis remained a significant factor, reducing the risk of CMV DNAemia at week 14 after allo-HSCT in acute leukemia (HR, 0.12; 95% CI, 0.04–0.42; $p=0.001$) (Table 3).

Patients in the valganciclovir and non-valganciclovir prophylaxis groups had similar transplant-related mortality and OS rates at week 48.

In addition to the incidence of CMV DNAemia at week 14, we also studied the impact of valganciclovir prophylaxis on survival. The results showed that the transplant-related mortality rates in the valganciclovir and non-valganciclovir prophylaxis groups were 10.0% and 3.1%, respectively ($p=0.239$); the OS rates at week 48 were 75.0% and 76.6%, respectively ($p=1.000$) (Table 2).
The log-rank test showed that the OS rate at week 48 after allo-HSCT was not significantly different between the valganciclovir and non-valganciclovir prophylaxis groups (75.0% versus 76.6%; p = 0.805) (Figure 2).

Cause of death analysis
Although patients in the valganciclovir and non-valganciclovir prophylaxis groups had similar acute GVHD (p = 0.143), chronic GVHD (p = 0.106), and relapse rates (p = 0.667) (Table 2), we analyzed the causes of death between the groups at weeks 14 and 48. The cumulative causes of death at week 14 (p = 0.261) and week 48 (p = 0.553) were not significantly different between the groups. Importantly, CMV infection did not result in mortality at weeks 14 and 48 among patients receiving low-dose valganciclovir prophylaxis. However, one death (CMV colitis) at week 14 and one death (CMV pneumonia) between week 14 and week 48 were CMV-infection related in the non-valganciclovir prophylaxis group (Table 4).

Table 2. Outcome comparison between patients with and without valganciclovir prophylaxis.

|                      | All patients N=84 (%) | Non-valganciclovir prophylaxis n=64 (%) | Valganciclovir prophylaxis n=20 (%) | p-value |
|----------------------|-----------------------|----------------------------------------|-------------------------------------|---------|
| Acute GVHD, n (%)    |                       |                                        |                                     | 0.143†  |
| No acute GVHD        | 37 (44.1)             | 25 (39.1)                              | 12 (60.0)                           |         |
| Grade I–II acute GVHD| 37 (44.1)             | 32 (50.0)                              | 5 (25.0)                            |         |
| Grade III–IV acute GVHD| 10 (11.9)            | 7 (10.9)                               | 3 (15.0)                            |         |
| Chronic GVHD, n (%)  |                       |                                        |                                     | 0.106*  |
| Without chronic GVHD | 75 (89.3)             | 55 (85.9)                              | 20 (100)                            |         |
| With chronic GVHD    | 9 (10.7)              | 9 (14.1)                               | 0 (0.0)                             |         |
| CMV DNAemia at week 14, n (%) |        |                                        |                                     | 0.012†  |
| No                    | 49 (58.3)             | 32 (50.0)                              | 17 (85.0)                           |         |
| Yes                   | 35 (41.7)             | 32 (50.0)                              | 3 (15.0)                            |         |
| Survival at week 48, n (%) |                |                                        |                                     | 1.000†  |
| Survival              | 64 (76.2)             | 49 (76.6)                              | 15 (75.0)                           |         |
| Death                 | 20 (23.8)             | 15 (23.4)                              | 5 (25.0)                            |         |
| Current status, n (%) |                       |                                        |                                     | 0.756†  |
| Survival              | 50 (59.5)             | 37 (57.8)                              | 13 (65.0)                           |         |
| Death                 | 34 (40.5)             | 27 (42.2)                              | 7 (35.0)                            |         |
| Relapse, n (%)        |                       |                                        |                                     | 0.667†  |
| No relapse            | 62 (73.8)             | 46 (71.9)                              | 16 (80.0)                           |         |
| Relapse               | 22 (26.2)             | 18 (28.1)                              | 4 (20.0)                            |         |

†Chi-square test.
*Fisher’s exact test.
CMV, cytomegalovirus; GVHD, graft-versus-host disease.
Adverse events of low-dose valganciclovir prophylaxis in allo-HSCT

Among the 20 patients receiving low-dose valganciclovir prophylaxis, eight (8/20; 40.0%) did not complete the prophylactic protocol, primarily because of neutropenia (n = 3), diarrhea (n = 1), CMV reactivation (n = 2), and leukemia relapse (n = 2). Three patients had renal function deterioration during valganciclovir prophylaxis. However, their renal functions returned to the normal range by decreasing the cyclosporine levels. With a 20% (4/20) discontinuation rate because of adverse events, low-dose valganciclovir prophylaxis was quite tolerable.

**Discussion**

This study found that the patients in the valganciclovir prophylaxis group had a lower possibility of
CMV DNAemia at week 14 after allo-HSCT than the patients in the non-valganciclovir prophylaxis group \( (p=0.012)\). Using the Fine–Gray test, the cumulative incidence of CMV DNAemia at week 14 was also lower in the patients with than in those without valganciclovir prophylaxis (15.0% versus 50.4%; \( p=0.006 \)). Multivariate analysis by Cox regression validated these data, showing that low-dose valganciclovir prophylaxis significantly reduced the risk of CMV DNAemia at week 14 by 88% (HR, 0.12; 95% CI, 0.04–0.42; \( p=0.001 \)). However, low-dose valganciclovir prophylaxis did not result in superior OS because the groups had similar OS rates at week 48 after allo-HSCT \( (p=0.805)\).

Previous studies have shown the efficacy of prophylactic valganciclovir in various types of solid organ transplantations. One randomized controlled trial showed that CMV (+) renal allograft recipients receiving preventive 450 mg valganciclovir twice a day for 100 days had significantly lower rates of CMV infection or diseases up to month 84 than patients treated with preemptive valganciclovir.\(^{12}\) Moreover, extended prophylaxis with 900 mg valganciclovir per day led to substantially lower CMV

### Table 4. Comparison of causes of death at weeks 14 and 48 between patients with and without valganciclovir prophylaxis.

|                      | All patient \( N=84 \) (%) | Non-valganciclovir prophylaxis \( N=64 \) (%) | Valganciclovir prophylaxis \( n=20 \) (%) | \( p \)-value |
|----------------------|----------------------------|-----------------------------------------------|------------------------------------------|--------------|
| Survival at week 14, \( n \) (%) |                            |                                               |                                          | 0.239*       |
| Yes                  | 80 (95.2)                  | 62 (96.9)                                    | 18 (90.0)                                |              |
| No                   | 4 (4.8)                    | 2 (3.1)                                      | 2 (10.0)                                 |              |
| Causes of death, \( n \) (%) |                            |                                               |                                          | 0.261%       |
| Relapse              | 1 (25.0)                   | 0 (0.0)                                      | 1 (50.0)                                 |              |
| GVHD                 | 1 (25.0)                   | 1 (50.0)                                    | 0 (0.0)                                  |              |
| CMV infection        | 1 (25.0)                   | 1 (50.0)                                    | 0 (0.0)                                  |              |
| Other infections     | 1 (25.0)                   | 0 (0.0)                                      | 1 (50.0)                                 |              |
| Others               | 0 (0.0)                    | 0 (0.0)                                      | 0 (0.0)                                  |              |
| Survival at week 48, \( n \) (%) |                            |                                               |                                          | 1.000%       |
| Yes                  | 64 (76.2)                  | 49 (76.6)                                    | 15 (75.0)                                |              |
| No                   | 20 (23.8)                  | 15 (23.4)                                    | 5 (25.0)                                 |              |
| Causes of death, \( n \) (%) |                            |                                               |                                          | 0.553%       |
| Relapse              | 14 (70.0)                  | 11 (73.3)                                    | 3 (60.0)                                 |              |
| GVHD                 | 2 (10.0)                   | 1 (6.7)                                      | 1 (20.0)                                 |              |
| CMV                  | 2 (10.0)                   | 2 (13.3)                                    | 0 (0.0)                                  |              |
| Infection            | 2 (10.0)                   | 1 (6.7)                                      | 1 (20.0)                                 |              |
| Others               | 0 (0.0)                    | 0 (0.0)                                      | 0 (0.0)                                  |              |

*Fisher’s exact test.  
¶Chi-square test.  
CMV, cytomegalovirus; GVHD: graft-versus-host disease.
pneumonitis in lung transplant recipients. However, more than 50% of patients needed to discontinue valganciclovir prophylaxis either temporally or permanently, primarily because of leukopenia. To minimize the valganciclovir-associated bone marrow suppression in allo-HSCT, our patients in the valganciclovir prophylaxis group received 450 mg/day valganciclovir from the day of absolute neutrophil engraftment to day 100 after allo-HSCT. Among patients receiving a low dose of valganciclovir CMV prophylaxis, we identified only three patients with CMV DNAemia before week 14 (3/20; 15%). This failure rate was similar to the clinically significant CMV infection incidence at week 14 in patients undergoing letermovir prophylaxis (7.7%). Furthermore, the incidence of CMV DNAemia at week 14 among patients without a lower dose of valganciclovir prophylaxis in our study and the incidence of clinically significant CMV infection at week 14 among patients without letermovir prophylaxis in the cohort by Marty et al. was quite comparable (50.0% versus 39.4%). Although a direct comparison is not possible, data such as these further enhance the validity of our study.

Although the dose of prophylactic valganciclovir in the current study was lower than the dose applied to kidney and lung transplantation, valganciclovir-induced adverse events remain problematic in the allo-HSCT setting. In our study cohort, four patients (three because of neutropenia and one because of diarrhea) in the valganciclovir prophylaxis group needed to prematurely and permanently discontinue valganciclovir use before week 14 (4/20; 20%). Compared with maribavir or brincidofovir, the toxicity of low-dose valganciclovir appears acceptable in allo-HSCT. However, only 10.2% of allo-HSCT recipients with letermovir prophylaxis needed to discontinue treatment before week 14, suggesting that letermovir could be more tolerable than low-dose valganciclovir for CMV prophylaxis in allo-HSCT. Notably, only two patients in the whole study cohort eventually died of CMV infection, suggesting that intensive CMV surveillance and appropriate preemptive ganciclovir treatment could effectively reduce CMV-related mortality in allo-HSCT. Furthermore, we did not observe CMV-related mortality among patients failing valganciclovir prophylaxis, suggesting that low-dose valganciclovir prophylaxis might not result in ganciclovir therapeutic resistance in allo-HSCT.

Identifying patients at high risk of CMV reactivation might be the best strategy to balance the benefits and adverse events associated with low-dose valganciclovir CMV prophylaxis in allo-HSCT. Although numerous factors may increase the possibility of CMV infection during allo-HSCT, the CMV seroprevalence rate in both recipients and donors remains a fundamental one. Unfortunately, the adult Taiwanese population’s CMV seropositivity rate can be as high as 90%, rendering CMV infection a more severe problem in Taiwanese allo-HSCT recipients than in those in Western countries. In addition to CMV seroprevalence, older age, donor types, and ATG-containing conditioning regimens are also associated with CMV infection in allo-HSCT. Our study showed that older age and haploidentical HSCT were significant factors for CMV reactivation. These results suggest that a low dose of valganciclovir may be potentially beneficial for CMV prevention in allo-HSCT, especially among older patients and patients undergoing haploidentical allo-HSCT.

Regarding OS, a low dose of valganciclovir prophylaxis did not result in a superior OS rate at week 48 after allo-HSCT. This result was not surprising because similar data were observed for letermovir prophylaxis, showing that patients in the letermovir prophylaxis and placebo groups had similar cumulative death rates from any cause at week 48. Moreover, in the current study, relapsed acute leukemia remained the primary cause of death in both groups of patients, accounting for 60.0% of deaths in the valganciclovir prophylaxis group and 73.3% of deaths in the non-valganciclovir prophylaxis group. Notably, only two patients in the whole study cohort eventually died of CMV infection, suggesting that intensive CMV surveillance and appropriate preemptive ganciclovir treatment could effectively reduce CMV-related mortality in allo-HSCT. Furthermore, we did not observe CMV-related mortality among patients failing valganciclovir prophylaxis, suggesting that low-dose valganciclovir prophylaxis might not result in ganciclovir therapeutic resistance in allo-HSCT.

Different transplant eras, the retrospective study design, and a limited number of patients in the valganciclovir prophylaxis group were notable limitations of the current study. In addition, we did not analyze the incidence of CMV DNAemia at week 24 because the CMV DNAemia surveillance schedule after week 14 could vary for each patient. Prospective and randomized-controlled studies with large numbers of patients are needed.
to validate our results. In summary, this study showed that with tolerable toxicity, low-dose valganciclovir prophylaxis significantly reduced CMV DNAemia at week 14 after allo-HSCT. However, this preventive approach did not result in superior OS at week 48 after allo-HSCT. Older patients and patients undergoing haploidentical allo-HSCT could benefit most from this treatment. Low-dose valganciclovir could be an alternative to letermovir to prevent CMV infection in allo-HSCT, especially in resource-limited countries.

Conflict of interest statement
Chieh-Lin Jerry Teng received an honorarium and consulting fees from Novartis, Roche, Takeda, Johnson & Johnson, Amgen, BMS Celgene, Kirin, AbbVie, and MSD. The other authors declare that they have no conflicts of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was partially supported by grants from TCVGH-1093704D.

ORCID iD
Chieh-Lin Jerry Teng https://orcid.org/0000-0001-9744-0368

References
1. Cornelissen JJ and Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127: 62–70.
2. Saadeh SS and Litzow MR. Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state. Expert Rev Hematol 2018; 11: 195–207.
3. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 2016; 3: e119–e127.
4. Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019; 19: e260–e272.
5. Chen K, Cheng MP, Hammond SP, et al. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv 2018; 2: 2159–2175.
6. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179–184.
7. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11: 284–292.
8. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369: 1227–1236.
9. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 2017; 377: 2433–2444.
10. Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 2015; 162: 1–10.
11. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
12. Witzke O, Nitschke M, Bartels M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial. Transplantation 2018; 102: 876–882.
13. Wiita AP, Roubinian N, Khan Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 2012; 14: 248–258.
14. Lu SC, Chin LT, Wu FM, et al. Seroprevalence of CMV antibodies in a blood donor population and premature neonates in the south-central Taiwan. Kaohsiung J Med Sci 1999; 15: 603–610.
15. Lin HC, Han SM, Hwang WL, et al. Cytomegalovirus infection and treatment in allogeneic hematopoietic stem cell
transplantation: a retrospective study from a single institution in an endemic area. Turk J Haematol 2017; 34: 159–166.

16. Lin CH, Su YJ, Hsu CY, et al. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. Transpl Infect Dis 2019; 21: e13096.

17. Wu JL, Ma HY, Lu CY, et al. Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect 2017; 50: 307–313.

18. Ljungman P, Schmitt M, Marty FM, et al. A mortality analysis of letermovir prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis 2020; 70: 1525–1533.

19. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.